Pharmacokinetics of nevirapine in HIV-infected children with and without malnutrition receiving divided adult fixed-dose combination tablets

被引:26
|
作者
Pollock, Louisa [2 ]
Else, Laura [1 ]
Poerksen, Goenke [2 ]
Molyneux, Elizabeth [2 ]
Moons, Peter [2 ]
Walker, Sarah [3 ]
Fraser, William [4 ]
Back, David [1 ]
Khoo, Saye [1 ]
机构
[1] Univ Liverpool, Dept Pharmacol & Therapeut, Liverpool L69 3BX, Merseyside, England
[2] Univ Malawi, Coll Med, Dept Paediat, Blantyre, Malawi
[3] MRC HIV Clin Trials Unit, London, England
[4] Royal Liverpool & Broadgreen Univ Hosp, Dept Clin Chem, Liverpool, Merseyside, England
关键词
Africa; paediatric; Triomune; ANTIRETROVIRAL THERAPY; METABOLISM; LAMIVUDINE; STAVUDINE; PLASMA; ACCESS;
D O I
10.1093/jac/dkp358
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
To determine the relationship between nutritional status and nevirapine exposure by comparing the pharmacokinetics of nevirapine in HIV-infected children of different ages with and without malnutrition receiving divided tablets of Triomune((R))30 (stavudine + lamivudine + nevirapine) in accordance with Malawi National Guidelines. Children were recruited in weight-based dosage bands and nutritional status classified according to weight for height. Total and unbound plasma nevirapine concentrations were measured over a full dosing interval. Multivariate linear and logistic regression analyses were performed to determine the effects of malnutrition, age, dose and other factors on nevirapine exposure and likelihood of achieving therapeutic nevirapine trough concentrations. Forty-three children were recruited (37 included for analysis). Mild to moderate malnutrition was present in 12 (32%) children; 25 (68%) were of normal nutritional status. There was no effect of malnutrition on any measure of total drug exposure or on the unbound fraction of nevirapine. Nevirapine exposure was strongly related to dose administered (P = 0.039) and to age (for every yearly increase in age there was an similar to 88% increase in the odds of achieving a therapeutic nevirapine concentration; P = 0.056, 95% confidence interval 0.983-3.585). Use of divided adult Triomune((R))30 tablets in treating young children results in significant underdosing. No independent effect of malnutrition on total and unbound nevirapine exposures was observed. These data support the use of bespoke paediatric antiretroviral formulations.
引用
收藏
页码:1251 / 1259
页数:9
相关论文
共 50 条
  • [21] Comparison of the pharmacokinetics and tolerability of montelukast/levocetirizine administered as a fixed-dose combination and as separate tablets
    Kim, Seokuee
    Ko, Jae-Wook
    Kim, Jung-Ryul
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 2018, 56 (09) : 443 - 450
  • [22] Fixed-dose darunavir/cobicistat in pregnancy of HIV-infected women, pharmacokinetic concerns
    Dash, Prasanta K.
    Boix, Vicente
    AIDS, 2021, 35 (08) : 1301 - 1303
  • [23] Is nevirapine dose-escalation appropriate in young, African, HIV-infected children?
    Fillekes, Quirine
    Mulenga, Veronica
    Kabamba, Desire
    Kankasa, Chipepo
    Thomason, Margaret J.
    Cook, Adrian
    Chintu, Chifumbe
    Gibb, Diana M.
    Walker, A. Sarah
    Burger, David M.
    AIDS, 2013, 27 (13) : 2111 - 2115
  • [24] Pharmacokinetics of generic and trade formulations of lamivudine, stavudine and nevirapine in HIV-infected Malawian children
    Corbett, Amanda H.
    Hosseinipour, Mina C.
    Nyirenda, Jean
    Kanyama, Cecelia
    Rezk, Naser L.
    Mkupani, Pax
    Sichali, Dorothy
    Tien, Hsiao
    Kashuba, Angela D. M.
    Mwansambo, Charles
    Weigel, Ralf
    Kazembe, Peter
    ANTIVIRAL THERAPY, 2010, 15 (01) : 83 - 90
  • [25] Pharmacokinetics of two generic fixed-dose combinations for HIV-infected children (Pedimune Baby & Pedimune Junior) are similar to the branded products in healthy adults
    L'homme, Rafaella F. A.
    Dijkema, Tim
    Warris, Adilia
    van der Ven, Andre J. A. M.
    Gibb, Diana M.
    Burger, David M.
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2007, 59 (01) : 92 - 96
  • [26] Population pharmacokinetics of nevirapine, zidovudine and didanosine after combination therapy in HIV-infected patients.
    Zhou, XJ
    Sheiner, LB
    D'Aquila, RT
    Hughes, MD
    Hirsch, MS
    Fischl, MA
    Johnson, VA
    Myers, M
    Sommadossi, JP
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 1998, 63 (02) : 182 - 182
  • [27] Integration of population pharmacokinetics and pharmacogenetics: an aid to optimal nevirapine dose selection in HIV-infected individuals
    Schipani, Alessandro
    Wyen, Christoph
    Mahungu, Tabitha
    Hendra, Heidy
    Egan, Deirdre
    Siccardi, Marco
    Davies, Gerry
    Khoo, Saye
    Faetkenheuer, Gerd
    Youle, Michael
    Rockstroh, Juergen
    Brockmeyer, Norbert H.
    Johnson, Margaret A.
    Owen, Andrew
    Back, David J.
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2011, 66 (06) : 1332 - 1339
  • [28] Fixed-dose combination of lamivudine, stavudine and nevirapine in the treatment of pediatric HIV-infection: A preliminary report
    Pensi, Tripti
    INDIAN PEDIATRICS, 2007, 44 (07) : 519 - 521
  • [29] Pharmacokinetics of lamivudine, zidovudine, and Nevirapine administered as a fixed-dose combination formulation versus co administration, of the individual products
    Marier, J. F.
    DiMarco, M.
    Guilbaud, R.
    Dodard, C.
    Morelli, G.
    Tippabhotla, S. K.
    Singla, A. K.
    Thudi, N. R.
    Monif, T.
    JOURNAL OF CLINICAL PHARMACOLOGY, 2007, 47 (11): : 1381 - 1389
  • [30] Pharmacokinetics of Nevirapine in HIV Infected Children from Resource Limited Settings Using Fixed Dose Anti-retroviral Combinations
    Manyarara, Tapiwa E.
    Khoza, S.
    Maponga, C. C.
    BRITISH JOURNAL OF PHARMACEUTICAL RESEARCH, 2016, 12 (03):